Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
In the last three months, 6 analysts have published ratings on Vericel (NASDAQ:VCEL), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 1 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 3 | 1 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $57.0, a high estimate of $60.00, and a low estimate of $55.00. This current average has increased by 2.24% from the previous average price target of $55.75.
In examining recent analyst actions, we gain insights into how financial experts perceive Vericel. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Caitlin Cronin | Canaccord Genuity | Announces | Buy | $57.00 | - |
George Sellers | Stephens & Co. | Raises | Overweight | $58.00 | $56.00 |
Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $60.00 | $55.00 |
Samuel Brodovsky | Truist Securities | Raises | Buy | $57.00 | $56.00 |
Ryan Zimmerman | BTIG | Lowers | Buy | $55.00 | $56.00 |
Joshua Jennings | TD Cowen | Announces | Buy | $55.00 | - |
To gain a panoramic view of Vericel's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Vericel analyst ratings.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Vericel's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.68% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vericel's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -8.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.96%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Vericel's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.28% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.39, caution is advised due to increased financial risk.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VCEL